285 related articles for article (PubMed ID: 23847058)
1. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children.
Langley JM; Carmona Martinez A; Chatterjee A; Halperin SA; McNeil S; Reisinger KS; Aggarwal N; Huang LM; Peng CT; Garcia-Sicilia J; Salamanca de la Cueva I; Cabañas F; Treviño-Garza C; Rodríguez-Weber MA; de la O M; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
J Infect Dis; 2013 Aug; 208(4):544-53. PubMed ID: 23847058
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.
Wang SY; Liu SZ; Chu K; Zhao Y; Zhu FC; Hu YM; Meng FY; Li JX; Luo L; Yang JY; Liu P; Yu J
Expert Rev Vaccines; 2017 Nov; 16(11):1155-1169. PubMed ID: 28870140
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.
Hu Y; Shao M; Hu Y; Liang Q; Jia N; Chu K; Xu L; Li J; Li C; Zhu F
Hum Vaccin Immunother; 2020 Jul; 16(7):1691-1698. PubMed ID: 32347785
[TBL] [Abstract][Full Text] [Related]
6. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
van de Witte S; Nauta J; Montomoli E; Weckx J
Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ
Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study.
Vesikari T; Nauta J; Lapini G; Montomoli E; van de Witte S
Int J Infect Dis; 2020 Mar; 92():29-37. PubMed ID: 31838217
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents.
Huang C; Fu X; Zhou Y; Mi F; Tian G; Liu X; Wu J; Ding C; Yan D; Li L; Yang S
Vaccine; 2020 Feb; 38(6):1332-1344. PubMed ID: 31948819
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial.
Langley JM; Wang L; Aggarwal N; Bueso A; Chandrasekaran V; Cousin L; Halperin SA; Li P; Liu A; McNeil S; Mendez LP; Rivera L; Innis BL; Jain VK
J Pediatric Infect Dis Soc; 2015 Sep; 4(3):242-51. PubMed ID: 26336604
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
Beran J; Peeters M; Dewé W; Raupachová J; Hobzová L; Devaster JM
BMC Infect Dis; 2013 May; 13():224. PubMed ID: 23688546
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials.
Moa AM; Chughtai AA; Muscatello DJ; Turner RM; MacIntyre CR
Vaccine; 2016 Jul; 34(35):4092-4102. PubMed ID: 27381642
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
Greenberg DP; Robertson CA; Landolfi VA; Bhaumik A; Senders SD; Decker MD
Pediatr Infect Dis J; 2014 Jun; 33(6):630-6. PubMed ID: 24445833
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial.
Wang L; Chandrasekaran V; Domachowske JB; Li P; Innis BL; Jain VK
J Pediatric Infect Dis Soc; 2016 Jun; 5(2):170-9. PubMed ID: 26407273
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
